DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note issued to investors on Sunday. The firm set a “hold” rating on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of DBV Technologies in a research report on Wednesday, February 21st.

DBV Technologies Price Performance

Shares of NASDAQ DBVT opened at $0.69 on Friday. The company has a market cap of $133.31 million, a price-to-earnings ratio of -1.77 and a beta of 0.75. The stock’s 50-day moving average is $0.77 and its two-hundred day moving average is $0.86. DBV Technologies has a 1-year low of $0.65 and a 1-year high of $2.37.

DBV Technologies (NASDAQ:DBVT) last released its earnings results on Thursday, March 7th. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.10. DBV Technologies had a negative net margin of 461.32% and a negative return on equity of 46.33%. The firm had revenue of $8.88 million for the quarter, compared to analyst estimates of $1.10 million. During the same period in the prior year, the firm earned ($0.23) earnings per share. Equities research analysts anticipate that DBV Technologies will post -0.88 earnings per share for the current fiscal year.

Hedge Funds Weigh In On DBV Technologies

Hedge funds have recently added to or reduced their stakes in the stock. Cowen AND Company LLC purchased a new position in shares of DBV Technologies during the fourth quarter worth about $49,000. Landscape Capital Management L.L.C. acquired a new stake in shares of DBV Technologies in the 3rd quarter valued at about $94,000. Finally, Optiver Holding B.V. grew its stake in DBV Technologies by 595.2% during the 3rd quarter. Optiver Holding B.V. now owns 274,874 shares of the company’s stock worth $374,000 after buying an additional 235,337 shares during the last quarter. 71.74% of the stock is currently owned by hedge funds and other institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.